New Delhi: The Indian Council of Medical Research (ICMR) has approved 21 institutions for participating in a randomised controlled study to assess the safety and efficacy of convalescent plasma to limit complications associated with COVID-19.
The sample size of the study is 452. Once 400 patients are enrolled, no more sites will be added. The clinical trial liability insurance has been bought centrally by the ICMR, officials said.
The therapy involves taking antibodies from the blood of a person who has recovered from COVID-19 and transfusing those antibodies into an active coronavirus patient to help kickstart the immune system to fight the infection.
“The ICMR has initiated a multi-centre clinical trial, titled ‘A Phase II, Open-Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease (PLACID Trial)’,” the apex health research body said.
Copyright Notice #
Please feel free to leave me a notice if you find this upload inappropriate.
Contact me personally if you are against an upload which
You may have rights the image or music, instead of contacting YouTube about a Copyright infringement…………
Thank you..
